| Literature DB >> 29483900 |
Rochelle C Joseph1, Nancy M Kim2, Nicholas R Sandoval1.
Abstract
The Clostridium genus is a large, diverse group consisting of Gram-positive, spore-forming, obligate anaerobic firmicutes. Among this group are historically notorious pathogens as well as several industrially relevant species with the ability to produce chemical commodities, particularly biofuels, from renewable biomass. Additionally, other species are studied for their potential use as therapeutics. Although metabolic engineering and synthetic biology have been instrumental in improving product tolerance, titer, yields, and feed stock consumption capabilities in several organisms, low transformation efficiencies and lack of synthetic biology tools and genetic parts make metabolic engineering within the Clostridium genus difficult. Progress has recently been made to overcome challenges associated with engineering various Clostridium spp. For example, developments in CRISPR tools in multiple species and strains allow greater capability to produce edits with greater precision, faster, and with higher efficiencies. In this mini-review, we will highlight these recent advances and compare them to established methods for genetic engineering in Clostridium. In addition, we discuss the current state and development of Clostridium-based promoters (constitutive and inducible) and reporters. Future progress in this area will enable more rapid development of strain engineering, which would allow for the industrial exploitation of Clostridium for several applications including bioproduction of several commodity products.Entities:
Keywords: CRISPR; biotechnology of microorganisms; clostridium; metabolic engineering; synthetic biology
Year: 2018 PMID: 29483900 PMCID: PMC5816073 DOI: 10.3389/fmicb.2018.00154
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Counter Selection markers used in Clostridium spp. and their mechanisms of selection. The native gene of interest (G.O.I) is represented in red, desired insert in blue, and the counter selection marker gene in dark purple. The green and blue bars represent regions of homology between the chromosome and donor plasmid. (A) ClosTron: RAM disrupted by a Group I intron (white triangle) is only active after the L1.LtrB intron is inserted into the chromosome; (B) pyrE complementation: PyrE catalyzes conversion of 5-fluoroorotic acid (5FOA) to 5-fluororotidine monophosphate (5FOMP) producing toxic fluorodeoxyuridine monophosphate (FdUTP); (C) Allele-Coupled Exchange: (1) double-crossover event at the pyrE locus results in truncated version of pyrE for counter selection with same mechanism as (B), (2) successful homologous recombination inserts a promoter-less copy of the pyrE gene directly downstream a native constitutive promoter, allowing production of uracil 5′ monophosphate (UMP). Note: must be performed on pyrE deficient strain; (D) MazF protein degrades mRNA at 5′-ACA-3′ sequences; (E) Cas9: successful homologous recombination gRNA-targeted double stranded break resulting in cell death.
CRISPR-based genetic editing and gene repression in Clostridium spp.
| Cas9 | 664 | NR | 100 | DNM | Wasels et al., | |||
| 500 | NR | 100 | 66 bp del | |||||
| 1,000 | NR | 100 | 306 bp rep | |||||
| 1,000 | NR | 67 | 50 bp del | Wang et al., | ||||
| 1,000 | 1.05 | 80 | 50 bp del | |||||
| 1,000 | 3.94 | 0 | 1,500 bp del | |||||
| 1,000 | 2.92 | 87 | 1,614 bp ins | |||||
| 1,000 | >99 | SNM | ||||||
| 1,000 | NR | 262 bp del | Wang et al., | |||||
| >50 | del | Nagaraju et al., | ||||||
| >50 | del | |||||||
| 500 | 0.2 | 100 | rep w/trunc. gene | Bruder et al., | ||||
| 1,000 | 0.38 | 100 | rep w/trunc gene | |||||
| 1,000 | 0.4 | NR | rep w/ Pthl::afp | |||||
| 100 | 1,000 bp del | Huang et al., | ||||||
| >75 | 2,600 bp del | |||||||
| 100 | 1,200 bp del | |||||||
| >50 | 570 bp del | |||||||
| 1,000 | 1.5 | NR | del | Wang S. et al., | ||||
| 1,000 | 1.6 | 75 | del | |||||
| 1,000 | 2.6 | 100 | 567 bp del | Pyne et al., | ||||
| Cas3 | 9.5 | 100 | N/A | 762 bp del | Pyne et al., | |||
| Cas9n | 1,000 | 100 | 23 bp del | Xu T. et al., | ||||
| 1,000 | NR | 23 bp del | ||||||
| 500 | 100 | 12 bp del | ||||||
| 200 | 100 | 12 bp del | ||||||
| 100 | <95 | 6 bp ins | ||||||
| 200 | <95 | 6 bp ins | ||||||
| 500 | >95 | 6 bp ins | ||||||
| 1,000 | >95 | 6 bp ins | ||||||
| 1,000 | 100 | NR | 710 bp ins | |||||
| 1,000 | 100 | NR | 1,720 bp ins | |||||
| 1,000 | 0 | NR | 3,000 bp ins | |||||
| 1,000 | 0 | NR | 6,000 bp ins | |||||
| 15.5 | 30 | 20 bp del | Li Q. et al., | |||||
| 7 | 20 bp del | |||||||
| 100 | 20 bp del | |||||||
| 19 | 20 bp del | |||||||
| 14.6 | 98 | 20 bp del | ||||||
| 150 | 0 | 20 bp del | ||||||
| 200 | 0 | 20 bp del | ||||||
| 500 | 30 | 20 bp del | ||||||
| 1,000 | 100 | 20 bp del | ||||||
| 50 | 20 bp del | |||||||
| 100 | 20 bp del | |||||||
| 40 | 20 bp del | |||||||
| 43 | 1149 bp del | |||||||
| NR | NR | 120 bp ins | Xu et al., | |||||
| dCas9 | 65–95 | Wang et al., | ||||||
| 45 | Li Q. et al., | |||||||
| 84 | ||||||||
| 95 | Wen et al., | |||||||
| Nontemplate | 90 | Plasmid-based | Bruder et al., | |||||
| Template | 20 | Plasmid-based | ||||||
| Nontemplate | NR | |||||||
| Nontemplate | NR | |||||||
All mentions of Cas9 refer to Streptococcus pyogenes-derived Cas9. Reported editing efficiencies are the fraction of successful mutants of total colonies screened. del, deletion; DNM, dinucleotide modification; ins, insertion; NR, Not reported; rep, replacement; SNM, Single nucleotide modification; trunc, truncation.
Cas3 is the effector protein in the native C. pasteurianum type I-B CRISPR system.
Targeted region downstream of Ccel_3198 gene.